medigraphic.com
ISSN 1028-4818 (Electronic)

2016, Number 5

<< Back Next >>

Mul Med 2016; 20 (5)

Risk factors for myocardial acute infarction in patients with diagnosis of hypertension

Escobar CPL, Mariño SRY

Language: Spanish
References: 17
Page: 129-143
PDF size: 190.61 Kb.


ABSTRACT

Introduction: coronary disease is the principal cause of cardiovascular death, a half of deaths is closely related to myocardial acute infarction.
Objective: to identify the influence of some risk factors in the appearance of myocardial acute infarction in patients with diagnosis of hypertension.
Method: a case-control analytical study was carried out on patients affected by myocardial acute infarction diagnosed with hypertension admitted in provincial hospital "Carlos M. de Cespedes", Granma province from January 1 to December 31 2015. The sample was composed by 120 patients, randomly assigned in proportion 1:1 (60 cases and 60 controls).
Results: analysis showed the majority of the factors searched constituted a risk for the appearance of myocardial acute infarction. While evaluating independent value of the different risk factors on the occurrence of disease, it was demonstrated the occurrence risk is 8, 23 times (CI 95 %, p: 0.000) more for those presenting severe hypertension, it constituted the greatest risk factor, followed by hypercholesterolemia and the evolution time greater or equal to fifteen years, with the probability of appearance of 6.47 y 5.53, respectively, both with CI 95 %, p: 0.000.
Conclusions: it is concluded that the obtained values in the logistic regression model for risk factors of independent influence in the appearance of hypertensive patients showed great probability to develop it.


REFERENCES

  1. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burniere M, Caulfieldf MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens [Internet]. 2009 [citado 17 Mar 2016]; 27(11):2121–58. Disponible en: http://www.ish.org.il/2009GuidelinesESH.pdf

  2. Tousoulis D, Koumallos N, Antoniades C, Antonopoulos AS, Bakogiannis B, Milliou A, et al. Genetic polymorphism on type 2 receptor of angiotensin II, modifies cardiovascular risk and systemic inflammation in hypertensive males. Am J Hypertens [Internet]. 2010 [citado 17 Mar 2016]; 23:237-42. Disponible en: http://search.proquest.com/openview/827a2743984c7d54f133b6dd7d658568/1?pq-origsite=gscholar

  3. Macías Guarasa I. Pronóstico y estancia media de los pacientes con angina inestable durante su ingreso en las unidades de cuidados intensivos o unidades coronarias españolas [Tesis doctoral]. Granada: Universidad de Granada; 2011. [citado 17 Mar 2016]. Disponible en: http://www.tesisenred.net/handle/10803/15427?show=full&locale-attribute=es

  4. Álvarez Aliaga A, González Aguilera JC. Algunos factores de riesgo de la cardiopatía hipertensiva. Rev Cubana de Med [Internet]. 2009 [citado 15 Feb 2016]; 48(4):139-51. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232009000400002&lng=es&nrm=iso&tlng=es

  5. Recomendaciones para guiar a los Médicos en la investigación biomédica en seres humanos. Bol of San Panam. 1990; 108 (5-6): 626 – 9.

  6. Backer G. de, Ambrosioni E, Borch-Johnsem K, Brotons C, Cifkova R, Dallongaville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joins Task Force of European and other Societies on Cardiovascular Diseases Prevention in Clinical Practice. Eur J Cardio Prev Rev [Internet]. 2003 [citado 17 Mar 2017]; 10 (supl 1):1-78. Disponible en: https://www.researchgate.net/publication/8511224_European_guidelines_on_cardiovascular_disease_prevention_in_clinical_practice_Third_Joint_Task_Force_of_European_and_other_Societies_on_Cardiovascular_Disease_Prevention_in_Clinical_Practice_constitut

  7. Velázquez-Monroy O, Rosas Peralta M, Lara Esqueda A, Pastelín Hernández G, Castillo C, Attie F, et al. Prevalencia e interrelación de enfermedades crónicas no transmisibles y factores de riesgo cardiovascular en México: resultados finales de la Encuesta Nacional de Salud (ENSA) 2000. Arch Cardiol Mex [Internet]. 2003 [citado 17 Mar 2016]; 73(1): 62-77. Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S1405-99402003000100009

  8. Avezum Á, Braga J, Santos Í, Guimarães HP, Marin-Neto JA, Piegas LS. Cardiovascular disease in South America: current status and opportunities for prevention. Heart [Internet]. 2009 [citado 17 Mar 2016]; 95: 1475-82. Disponible en: http://heart.bmj.com/content/95/18/1475.abstract

  9. Piskorz D, Quaglino M, Pigozzi F, Vitelleschi M. Importancia de las variables no hemodinámicas en el desarrollo de hipertrofia ventricular izquierda en hipertensión. Rev Fed Arg Cardiol [Internet]. 2010 [citado 12 Ene 2016]; 39(4):288-93. Disponible en: http://www.fac.org.ar/1/revista/10v39n4/art_orig/arorig03/piskorz.php

  10. D’Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care the Framingham heart study. Circulation [Internet]. 2008 [citado 10 Mar 2016]; 117:743-53. Disponible en: http://circ.ahajournals.org/content/117/6/743.long.

  11. Marshall T. The effect of blood pressure and cholesterol variability on the precision of Framingham cardiovascular risk estimation: a simulation study. J Hum Hypertens [Internet]. 2010 [citado 18 Ene 2016]; 24:1-8. Disponible en: http://www.nature.com/jhh/journal/v24/n10/full/jhh2009114a.html.

  12. Cordero A, Moreno J, Alegría E. Hipertensión arterial y síndrome metabólico. Rev Esp Cardiol [Internet]. 2005 [citado 17 Mar 2016]; 5(supl D): 38 – 45. Disponible en: http://www.revespcardiol.org/es/hipertension-arterial-sindrome-metabolico/articulo/13083447/?esMedico=1

  13. López-Jiménez F, Corté s-Bergoderi M. Obesidad y corazón. Rev Esp Cardiol [Internet]. 2011 [citado 21 Mar 2016]; 64(2):140-9. Disponible en: http://www.revespcardiol.org/es/obesidad-corazon/articulo/13191034/.

  14. Windham BG, Griswold ME, Farasat SM, Ling SM, Carlson O, Egan JM, et al. Influence of leptin, adiponectin and resistin on the association between abdominal adiposity and arterial stiffness. Am J Hypertens [Internet]. 2010 [citado 21 Mar 2016]; 23:501-7. Disponible en: http://ajh.oxfordjournals.org/content/23/5/501.full.

  15. Díez J, Frohlich ED. A translational approach to hypertensive heart disease. Hypertension [Internet]. 2010 [citado 17 Mar 2016]; 55(1):1-8. Disponible en: http://hyper.ahajournals.org/content/55/1/1

  16. Alfonso Guerra JP. Daño en órganos relacionados con la hipertensión arterial. Factores de riesgo modificables. En: Hipertensión arterial en la atención primaria de salud [Internet]. La Habana: Ciencias Médicas; 2009. p. 129-39. [citado 17 Mar 2016]. Disponible en: http://www.bvs.sld.cu/libros/hipertension_arterial/completo.pdf

  17. Chobarian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The Seventh Report of the Joint National Comitte on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC7) report. JAMA may [Internet]. 2003 [citado 17 Mar 2016]; 289(19):2560-71. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/12748199




2020     |     www.medigraphic.com